-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $273 Price Target

Benzinga·04/09/2026 13:01:06
Listen to the news
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $273 price target.